Although our microarray meta-analyses did not show a relationship between CDH11 (or N-cadherin) to prostate cancer (Supplementary Fig. S1A) the datasets we examined, did not indicate, and likely do not include androgen resistant forms of the disease in which both N-cadherin and CDH11 are elevated [27;28]. Here, CDH2 is linked to prostate carcinoma.